scholarly journals Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study

BMJ Open ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. e033427
Author(s):  
Jason C Hsu ◽  
Chen-Fang Wei ◽  
Szu-Chun Yang ◽  
Peng-Chan Lin ◽  
Yang-Cheng Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Time Series ◽  
Survival Rate ◽  
Targeted Therapies ◽  
Cancer Survival ◽  
Early Stage ◽  
Survival Rates ◽  
Interrupted Time Series ◽  
New Drugs ◽  
Lung Cancer Survival

ObjectivesTwo oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were to determine the trends in lung cancer burden and examine changes in lung cancer-related survival rates and mortality following the launch of these new drugs.SettingYearly lung cancer-related data (1994–2013), including incidence, number of newly diagnosed patients, survival rate and mortality, were retrieved from the Taiwan Cancer Registry Database.Design and outcome measuresUsing a time series design with autoregressive integrated moving average model, we investigated and projected trends in the incidence and early diagnosis of lung cancer in Taiwan. We also estimated the changes in survival rates and mortality following the launch of targeted therapies using interrupted time series and segmented regression models.ResultsThe age-standardised incidence of lung cancer increased from 22.53 per 100 000 people in 1994 to 34.09 in 2013, and it was projected to reach 38.98 by 2020. The rate of early-stage NSCLC at diagnosis increased from 12.63% in 2004 to 23.99% in 2013, and it was projected to reach 32.95% by 2020. The 2-year lung cancer survival increased by 19.81% (95% CI 14.90% to 24.71%) 3 years following the launch of gefitinib. Lung cancer mortality declined by 5.97% (95% CI −8.20% to −3.73%) 3 years following the launch of gefitinib.ConclusionsLung cancer survival rate increased and mortality decreased significantly following the launch of gefitinib and erlotinib in Taiwan.

scholarly journals Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival

CHEST Journal ◽  
2017 ◽  
Vol 152 (3) ◽  
pp. 587-597 ◽  
Author(s):  
Samir Soneji ◽  
Nichole T. Tanner ◽  
Gerard A. Silvestri ◽  
Christopher S. Lathan ◽  
William Black
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Early Stage ◽  
Ethnic Disparities ◽  
Racial And Ethnic Disparities ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Survival ◽  
Stage Lung Cancer

scholarly journals Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival

JCI Insight ◽  
2018 ◽  
Vol 3 (13) ◽  
Author(s):  
Geoffrey J. Markowitz ◽  
Lauren S. Havel ◽  
Michael J.P. Crowley ◽  
Yi Ban ◽  
Sharrell B. Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Survival ◽  
Stage Lung Cancer

scholarly journals Helical Computed Tomography has a Role in the Screening of Lung Cancer -- The Pro Argument

2004 ◽  
Vol 11 (3) ◽  
pp. 214-216 ◽  
Author(s):  
Milan Patel
Keyword(s):  
Computed Tomography ◽  
Lung Cancer ◽  
Health Care ◽  
Colon Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Helical Computed Tomography ◽  
Western World ◽  
The Past ◽  
Lung Cancer Survival

In 2003, approximately 21,000 new cases of lung cancer were diagnosed across Canada. Nearly 19,000 Canadians died of this devastating disease that year (1). Worldwide, there are over one million cases identified annually (2). In the Western world, more patients die of lung cancer than from breast, prostate and colon cancer combined. Despite these figures, lung cancer has remained low on the health care agenda. In the past three decades, there has been little improvement in observed lung cancer survival rates, with overall five-year survival rates approaching 15% (3).

scholarly journals Variation in lung cancer survival rates between countries: Do differences in data reporting contribute?

2006 ◽  
Vol 100 (9) ◽  
pp. 1642-1646 ◽  
Author(s):  
Claire A. Butler ◽  
Karen M. Darragh ◽  
Graeme P. Currie ◽  
Wendy J.A. Anderson
Keyword(s):  
Lung Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Data Reporting ◽  
Lung Cancer Survival

scholarly journals Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016

2021 ◽  
Vol 27 ◽  
Author(s):  
Krisztina Bogos ◽  
Zoltan Kiss ◽  
Lilla Tamási ◽  
Gyula Ostoros ◽  
Veronika Müller ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Cancer Survival ◽  
Survival Rates ◽  
Cancer Type ◽  
Lung Cancer Patients ◽  
First Time ◽  
Lung Cancer Survival

Objective: Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund database.Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between January 1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer.Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2 and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n = 16,362) had 23% better survival (HR: 0.77, 95% confidence interval (CI): 0.75–0.79; p < 0.001) than males (n = 25,492). The highest survival rates were found in the 20–49 age cohort (5Y = 31.3%) and if the cancer type was adenocarcinoma (5Y = 20.5%). We measured 5.3% improvement (9.2% adjusted) in lung cancer survival comparing the period 2015–2016 to 2011–2012 (HR: 0.95 95% CI: 0.92–0.97; p = 0.003), the highest at females <60 year (0.86 (adjusted HR was 0.79), interaction analysis was significant for age and histology types.Conclusion: Our study provided long-term Lung cancer survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to–and at the higher end of–rates registered in other East-Central European countries (7.7%–15.7%).

Sign in / Sign up

Export Citation Format

Share Document